Clinical Trials · NCT03798912

A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform

CompletedPhase 1Octreotide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
RANI Therapeutics
Enrollment
62
Start date
Jul 2019
Locations
1 site, Australia
Primary endpoint
Incidence and kind of adverse events possibly related to the RaniPill capsule
View Octreotide compound reference